# Safety and Tolerability of PNT001 in Patients With Acute Traumatic Brain Injury (TBI)

> **NCT04677829** · PHASE1 · TERMINATED · sponsor: **Pinteon Therapeutics, Inc** · enrollment: 1 (actual)

## Conditions studied

- Traumatic Brain Injury

## Interventions

- **BIOLOGICAL:** PNT001
- **BIOLOGICAL:** %5 dextrose for infusion

## Key facts

- **NCT ID:** NCT04677829
- **Lead sponsor:** Pinteon Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-29
- **Primary completion:** 2021-04-12
- **Final completion:** 2021-04-12
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** The study was terminated due to administrative, non-safety related reasons.
- **Last updated:** 2022-06-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04677829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04677829, "Safety and Tolerability of PNT001 in Patients With Acute Traumatic Brain Injury (TBI)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04677829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*